Utility of Amplification Refractory Mutation System PCR for the detection of JAK2 mutation in Chronic Myeloproliferative Disorders.
- Prince Fahd Bin Sultan Research chair, Division of cancer Molecular Genetics, Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk, Kingdom of Saudi Arabia.
- Deparment of Clinical Pathology, King Fahad Special Hospital, Ministry of Health Kingdom of Saudi Arabia.
- Cite This Article as
- Corresponding Author
Detection of the JAK2 V617F mutation is helpful in differential diagnosis, prognosis, and predication of therapeutic response in CMPD disorders. Because the mutation can be present in a small proportion of granulocytic populations in MPD patients, a highly sensitive detection method is required. The study was aimed to optimize ARMS-PCR for the detection of JAK2V617F mutations .This study was conducted at Prince Fahd Bin Sultan Research Chair .Fifty subjects were registered from the King Khaled Hospital of Tabuk -Northwestern part of Saudi Arabia among which 25 newly diagnosed MPD patients and 25 healthy controls. DNA was extracted done using DNA extraction Kit from Qiagen .ARMS was optimized in which a a primers were designed in such a way that it is able to discriminate among templates that differ by a single nucleotide residue in one tube reaction.Both cases and controls were tested for JAK2 mutations by ARMS-PCR. Demographic data, spleen size, hemoglobin level, white blood cell and platelet counts were recorded. Independent sample t-test was used to study the correlation of JAK2 mutations with age, haemoglobin, blood counts and spleen size. Fisher\'s exact test was applied to compare disease progression in mutation positive and negative cases. This study was conducted on 25 newly diagnosed MPD patients among which 17 were polycythemia vera,5 Essential thrombocytopenia and 3 primary myelofibrosis and 25 healthy controls. Both cases and controls were tested for JAK2 mutations by ARMS-PCR. The JAK2 mutation was detected in 17/25 samples among which 13 were Polycythemia Vera, 02 from Essential thrombocythemia, 01 from Primary myelofibrosis. The JAK2 mutation was not detected in any of the healthy controls by ARMS-PCR. The main advantage of ARMS was that the amplification step and the diagnostic steps were combined, in that the presence of an amplified product indicates the presence of a particular allele and vice versa. For routine diagnosis, this characteristic of ARMS means that it is a very time-efficient method.It was concluded that the ARMS-PCR assay optimized allows the discrimination between homozygous and heterozygous individuals with the JAK2 V617F mutation and has a key role in acting as a reliable screening test for the presence or absence of the mutation in individuals with MPDs. The test will be potentially useful to follow minimal residual disease when targeted therapies against JAK2 kinase become available. The test is therefore a simple, fast, and inexpensive procedure that does not entail any special equipment other than a thermocycler.
- Dameshek W. Some speculations on the myeloproliferative syndromes.Blood1951;?6: 372?375.
- Nelson ME, Steensma DP (2006)JAK2?V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma 47: 177?194.
- Goldman JM, Melo JV. Chronic myeloid leukemia ? advances in biology and new approaches to treatment.?N Engl J Med2003;?349: 1451?1464.
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.?Blood2005;?105: 2640?2653.
- Greiner, TC.Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.?Am J Clin Pathol.?2006;?125:?651?653
- Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ?et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer Cell2005;?7: 387?397.
- James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout Cet al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.?Nature?2005;?434: 1144?1148.
- Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med.2005;352:1779?1790
- Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Hematology (Am Soc Hematol Educ Program)?2005:195?200.
- Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group .Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. 2005 Dec 3; 366(9501):1945-53.
- McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.?Leukemia.?2006;20:168
- Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.?Blood.2005;106:3370?3373
- Steensma, DP.JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.?J Mol Diagn.?2006;?8:?397?411
- Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.?J Mol Diagn.?2006;8:397?411
- Ma W, Kantarjian H, Zhang X, Yeh C-H, Zhang ZJ, et al. Mutation profile of?JAK2transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009, 11: 49?53.
- McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.?Leukemia.?2006;20:168?171
- Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D?et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.?Br J Haematol 2005;?131: 166?171.
- Vannucchi AM, Guglielmelli P, Antonioli E, Mappa S, Pancrazzi A, Bogani Cet al. Inconsistencies in the association between the JAK2 mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.?Br J Haematol? 2006;?132: 652?654.
- James, C, Ugo, V, Le Couedic, JP, Staerk, J, Delhommeau, F, Lacout, C, Garcon, L, Raslova, H, Berger, R, Bennaceur-Griscelli, A, Villeval, JL, Constantinescu, SN, Casadevall, N, and Vainchenker, W.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.?Nature.?2005;434:?1144?1148
- Tefferi, A, Thiele, J, Orazi, A, Kvasnicka, HM, Barbui, T, Hanson, CA, Barosi, G, Verstovsek, S, Birgegard, G, Mesa, R, Reilly, JT, Gisslinger, H, Vannucchi, AM, Cervantes, F, Finazzi, G, Hoffman, R, Gilliland, DG, Bloomfield, CD, and Vardiman, JW.Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.?Blood.?2007;?110:?1092?1097
- Pietra, D, Li, S, Brisci, A, Passamonti, F, Rumi, E, Theocharides, A, Ferrari, M, Gisslinger, H, Kralovics, R, Cremonesi, L, Skoda, R, and Cazzola, M.Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.?Blood.?2008;?111:?1686?1689
- Grunebach, F, Bross-Bach, U, Kanz, L, and Brossart, P.Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.?Leukemia.?2006;?20:?2210?2211
- Tefferi, A and Pardanani, A.Mutation screening for JAK2V617F: when to order the test and how to interpret the results.?Leuk Res.?2006;?30:?739?744
- Baxter, EJ, Scott, LM, Campbell, PJ, East, C, Fourouclas, N, Swanton, S, Vassiliou, GS, Bench, AJ, Boyd, EM, Curtin, N, Scott, MA, Erber, WN, and Green, AR.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.?Lancet.?2005;?365:1054?1061
- Levine, RL, Wadleigh, M, Cools, J, Ebert, BL, Wernig, G, Huntly, BJ, Boggon, TJ, Wlodarska, I, Clark, JJ, Moore, S, Adelsperger, J, Koo, S, Lee, JC, Gabriel, S, Mercher, T, D\'Andrea, A, Frohling, S, Dohner, K, Marynen, P, Vandenberghe, P, Mesa, RA, Tefferi, A, Griffin, JD, Eck, MJ, Sellers, WR, Meyerson, M, Golub, TR, Lee, SJ, and Gilliland, DG.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer Cell.?2005;?7:387?397
- Jones, AV, Kreil, S, Zoi, K, Waghorn, K, Curtis, C, Zhang, L, Score, J, Seear, R, Chase, AJ, Grand, FH, White, H, Zoi, C, Loukopoulos, D, Terpos, E, Vervessou, EC, Schultheis, B, Emig, M, Ernst, T, Lengfelder, E, Hehlmann, R, Hochhaus, A, Oscier, D, Silver, RT, Reiter, A, and Cross, NC.Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.?Blood.?2005;?106:?2162?2168.
[Rashid Mir, Abu-Duhier FM, Jamsheed J, Fawzia Sharaf & Nabil Burrow. (2017); Utility of Amplification Refractory Mutation System PCR for the detection of JAK2 mutation in Chronic Myeloproliferative Disorders. Int. J. of Adv. Res. 5 (1). 829-837] (ISSN 2320-5407). www.journalijar.com
Article DOI: 10.21474/IJAR01/2822 DOI URL: http://dx.doi.org/10.21474/IJAR01/2822
Share this article
This work is licensed under a Creative Commons Attribution 4.0 International License.